Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBX-2400 in AML and Myelofibrosis
NCT04709458Phase 1Unknown
- Sponsor
- Taiga Biotechnologies, Inc.
- Start
- Sep 2022
- Primary completion
- Aug 2024
- Modality
- Hematopoietic Stem Cells
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of TBX-2400 in acute myeloid leukemia (AML) and myelofibrosis (MF), sponsored by Taiga Biotechnologies, Inc. Primary endpoints: Incidence of adverse events according to NCI-CTCAE Version 5.0 at 2 years and Transplant engraftment at 1 year. Status: unknown.
02
Drugs
TBX-2400
03
Conditions
acute myeloid leukemia (AML)myelofibrosis (MF)
Beyond the preview
Go deeper on NCT04709458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04709458.